High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.

@article{Fontein2012HighNI,
  title={High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.},
  author={Duveken B. Y. Fontein and Johan W. R. Nortier and Gerrit Jan Liefers and Hein Putter and Elma M Meershoek-Klein Kranenbarg and Joan van den Bosch and Eduard Maartense and Emiel J. Th. Rutgers and Cornelis J. H. van de Velde},
  journal={European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology},
  year={2012},
  volume={38 2},
  pages={110-7}
}
AIMS The aim of this study was to investigate non-compliance to aromatase inhibitors and factors associated with early treatment discontinuation in the extended adjuvant setting. METHODS The IDEAL trial is a prospective, open-label phase-III trial comparing 2.5 with 5 years of extended adjuvant letrozole (LET) in hormone receptor positive (HR+) postmenopausal early breast-cancer patients after 5 years of adjuvant endocrine therapy (ET). The purpose of this study was to assess non-compliance… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…